A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

NCT00090623 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Degeneration

Interventions

DRUG: rhuFab V2 (ranibizumab)

Sponsor

Genentech, Inc.